Calgary, Canada (PressExposure) September 16, 2009 -- Calgary-based MPowRx Health and Wellness Products Inc. (MPowRx) today announced that the United States Patent and Trademark Office has granted United States Patent 7,533,674 entitled âTongue Retention Deviceâ. The awarded Patent broadly covers the MPowRxâ¢ Snoring Solution and underscores the innovate nature of the device. This Patent complements a previously awarded US Design Patent D461,240 entitled âTongue Retention Deviceâ.
The Company today further announced that it has received 510K premarket notification from the FDA for the MPowRxâ¢ Snoring Solution. The Company has satisfied the agencyâs requirements as a Class II medical device, permitting it to begin marketing the device in the USA. Acting through its U.S. agent, regulatory firm Emergo Group Inc., (http://www.emergogroup.com/) the Company is proceeding with expansion plans across the border.
The MPowRxâ¢ Snoring Solution (www.isleepsound.com), distributed in Canada by a leading national Distributor Patterson Dental (www.pattersondental.com), is being embraced by dental professionals who recognize the large unmet clinical need in the treatment of snoring.
âThe issuance of this patent combined with FDA clearance, positions the Company for significant growth in a marketplace where few cost effective treatment options are supported by a proprietary technology and clinical efficacyâ, says Nancy Markley of MPowRx. âWe are excited to extend this clinically proven device to the 56 million Americanâs who suffer from snoringâ, adds Markley. The MPowRxâ¢ Snoring Solution was developed by noted Dr. Leslie Dort, Calgary dentist and dental sleep medicine researcher, in response to growing incidence, and unmet need for a simple, cost effective and clinically proven treatment.